Blinatumomab
CD19xCD3 bispecific antibody
A bispecific antibody that links T cells with CD19-marked leukemia cells.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
- Generic name
- blinatumomab
- Marketed brand names
- Blincyto
- Route
- Continuous intravenous infusion
- Drug class
- CD19xCD3 bispecific antibody
Registration status
Registration status and availability in Indonesia must be confirmed directly with the health facility or authorized distributor. This page is not a source of marketing approval status.
Not a marketing-authorisation source
TanyaKanker does not state a drug's marketing approval status in Indonesia. Confirm official status only through a healthcare facility, BPOM, or an authorised distributor.
Access considerations
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
What needs verification
- Indications approved in the country where the drug is used.
- Compliance with the patient's latest biological marker examination results.
- Plan to monitor side effects and interactions with other drugs being used.
Related
Sources
- NCI Drug Dictionary(lembaga)
Studies related to this drug marker
NCT05633615Phase 2CAR-T cell therapy
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy, Immunotherapy, Chemotherapy
United States95 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05633615Not verified
NCT06528301Phase 1Combination regimen
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
United States, Australia9 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06528301Not verified
NCT07532525Phase 1CAR-T cell therapy
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07532525Not verified
NCT05850234Phase 1 / Phase 2CAR-T cell therapy
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Multiple Myeloma | biomarker: CD19 | CAR-T cell therapy, Stem cell transplant
United States34 registry sites
Why this appears: Appears because it is recorded for Multiple Myeloma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05850234Not verified
Request cost and access questions
We prepare cost and availability questions that need direct confirmation from a facility.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- CD19
Biomarker
Reason: Targets this marker
- Immunotherapy
Treatment category
Reason: Uses this drug
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Clinical trial
Reason: Uses this drug
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Clinical trial
Reason: Uses this drug
- CD19 positive
Molecular alteration
Reason: Related to this page
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Clinical trial
Reason: Uses this drug
To check
- Cost and access questions
Tool
Reason: Prepare questions to ask a facility
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.